Selamet Tierney Elif Seda, Newburger Jane W, Gauvreau Kimberlee, Geva Judith, Coogan Elizabeth, Colan Steven D, de Ferranti Sarah D
Department of Cardiology, Children's Hospital, Boston, MA 02155, USA.
J Pediatr. 2009 Jun;154(6):901-5. doi: 10.1016/j.jpeds.2008.12.028. Epub 2009 Feb 12.
To test prospectively the reproducibility and feasibility of endothelial pulse amplitude testing (Endo-PAT), a novel Food and Drug Administration-approved technology, in healthy adolescents.
We performed Endo-PAT testing on 2 different days separated by no more than 7 days in 30 healthy fasting adolescents, ages 13 to 19 years, to assess reproducibility and feasibility. The reported level of discomfort, as measured on a pain scale of 1 to 5, was documented.
The mean difference in paired Endo-PAT indices was 0.12 (95% CI, -0.09-0.33; P = .24; intraclass correlation coefficient, 0.78), and the within-subject variation of Endo-PAT index was 0.16. The Endo-PAT index on test days 1 and 2 were 1.91 +/- 0.57 and 1.78 +/- 0.51 (mean plus or minus SD), respectively. All attempted studies (100%) were completed (95% CI, 88%-100%), and all completed studies (100%) could be analyzed (95% CI, 88%-100%). The median pain score was 1 on both days.
In healthy adolescents, Endo-PAT is feasible and has excellent reproducibility. This technology may provide an easy and reliable means of assessing endothelial function in the pediatric population.
前瞻性地测试一种经美国食品药品监督管理局批准的新型技术——内皮脉搏振幅测试（Endo-PAT）在健康青少年中的可重复性和可行性。
我们对30名年龄在13至19岁的健康空腹青少年在不超过7天的2个不同日期进行了Endo-PAT测试，以评估其可重复性和可行性。记录了以1至5疼痛量表衡量的报告不适程度。
配对的Endo-PAT指数的平均差异为0.12（95%可信区间，-0.09 - 0.33；P = 0.24；组内相关系数，0.78），Endo-PAT指数的受试者内变异为0.16。第1天和第2天的Endo-PAT指数分别为1.91±0.57和1.78±0.51（均值±标准差）。所有尝试的研究（100%）均完成（95%可信区间，88% - 100%），且所有完成的研究（100%）均可进行分析（95%可信区间，88% - 100%）。两天的疼痛评分中位数均为1。
在健康青少年中，Endo-PAT是可行的且具有出色的可重复性。该技术可能为评估儿科人群的内皮功能提供一种简单可靠的方法。
